Enhancing stem cell mobility: New hope for treatment of cardiovascular complications in patients with diabetes?

Diabetes

Volumn 64, Issue 8, 2015, Pages 2704-2707

  Spinetti, Gaia ^a   Mangialardi, Giuseppe ^b   Specchia, Claudia ^a,c   Madeddu, Paolo ^b  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLERIXAFOR; VASCULOTROPIN RECEPTOR 2; HETEROCYCLIC COMPOUND;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CELL MOTILITY; CROSS REACTION; DIABETES MELLITUS; HEART FUNCTION; HEART INFARCTION; HUMAN; MONONUCLEAR CELL; MORBIDITY; NOTE; PRIORITY JOURNAL; STEM CELL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; HEMATOPOIETIC STEM CELL; MALE; STEM CELL MOBILIZATION;

DIABETES MELLITUS, TYPE 1; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE;

EID: 84943652152     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0433     Document Type: Note

References (36)

1. Albiero M, Poncina N, Tjwa M., et al. Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. Diabetes 2014; 63:1353-1365
2. Spinetti G, Cordella D, Fortunato O., et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 2013; 112:510-522
3. Oikawa A, Siragusa M, Quaini F., et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010; 30:498-508
4. DiPersio JF. Diabetic stem-cell "mobilopathy". N Engl J Med 2011; 365: 2536-2538
5. Werner N, Kosiol S, Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999-1007
6. Fadini GP, Maruyama S, Ozaki T., et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 2010; 5:e11488
7. Schmidt-Lucke C., Rössig L, Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111:2981-2987
8. Spinetti G, Specchia C, Fortunato O., et al. Migratory activity of circulating mononuclear cells is associated with cardiovascular mortality in type 2 diabetic patients with critical limb ischemia. Diabetes Care 2014; 37:1410-1417
9. Fadini GP, Boscaro E, de Kreutzenberg S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010; 33:1097-1102
10. Albiero M, Avogaro A, Fadini GP Restoring stem cell mobilization to promote vascular repair in diabetes. Vascul Pharmacol 2013; 58:253-258
11. Cashen AF, Lazarus HM, Devine SM Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577-588
12. Ferraro F, Lymperi S, Mendez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011; 3: 104ra101
13. Fadini GP, Avogaro A. Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease: a meta-regression analysis. Int J Cardiol 2013; 168:892-897
14. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77:1655-1664
15. Fadini GP, Fiala M, Cappellari R., et al. Diabetes limits stem cell mobilization following G-CSF but not plerixafor. Diabetes 2015; 64:2969-2977
16. Harada M, Qin Y, Takano H., et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11:305-311
17. Sugano Y, Anzai T, Yoshikawa T., et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 2005; 65:446-456
18. Kang HJ, Kim HS, Zhang S.Y., et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363:751-756
19. Valgimigli M, Rigolin GM, Cittanti C, et al Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005; 26:1838-1845
20. Ince H, Petzsch M, Kleine H.D., et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005; 112:3097-3106
21. Abdel-Latif A., Bolli R, Zuba-Surma EK, Tleyjeh I.M., Hornung CA, Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2008; 156:216-226.e9
22. Zohlnhöfer D., Dibra A, Koppara T., et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol 2008; 51:1429-1437
23. Moazzami K, Roohi A, Moazzami B. Granulocyte colony stimulating factor therapy for acute myocardial infarction. Cochrane Database Syst Rev 2013; 5: CD008844
24. Takano H, Hasegawa H, Kuwabara Y., et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 2007; 122:41-47
25. Shepherd RM, Capoccia BJ, Devine S.M., et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood 2006; 108:3662-3667
26. Rüder C., Haase T, Krost A., et al. Combinatorial G-CSF/AMD3100 treatment in cardiac repair after myocardial infarction. PLoS One 2014; 9:e104644
27. Spinetti G, Fortunato O, Caporali A., et al. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res 2013; 112:335-346
28. Satoh N, Shimatsu A, Himeno A., et al. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care 2010; 33:e7
29. Fadini GP, de Kreutzenberg SV, Boscaro E, et al. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 2013; 56: 1856-1866
30. Askari AT, Unzek S, Popovic Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362:697-703
31. Yamaguchi J, Kusano KF, Masuo O, et al Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003; 107:1322-1328
32. Peled A, Grabovsky V, Habler L., et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999; 104:1199-1211
33. Salcedo R, Wasserman K, Young H.A., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999; 154:1125-1135
34. Kanda S, Mochizuki Y, Kanetake H. Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase. J Biol Chem 2003; 278:257-262
35. Melchionna R, Porcelli D, Mangoni A., et al. Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis. FASEB J 2005; 19:629-631
36. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett 2014; 352:36-53